Pharma BD Deal Intelligence
Boehringer Ingelheim acquired NBE Therapeutics for $1.5B for breast and lung cancer treatments.
Acquisition agreement with Boehringer Ingelheim for NBE-Therapeutics first major biotech exit for PPF Group.
Source summaries from our enrichment pipeline; follow links for originals.
All 4 sources with sentiment breakdown →
Boehringer Ingelheim acquired NBE Therapeutics for $1.5B for breast and lung cancer treatments.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Boehringer Ingelheim GmbH / NBE Therapeutics (this deal) | 2020 | $1.5B | 28 |
| Boehringer Ingelheim GmbH / Amgen Inc. (Fremont manufacturing facility) | 2011 | — | 77 |
| Boehringer Ingelheim GmbH / AMAL Therapeutics SA | 2019 | $366M | — |
| Boehringer Ingelheim GmbH / Bridge Biotherapeutics, Inc. | 2019 | $1.2B | — |
| Boehringer Ingelheim GmbH / NBE-Therapeutics AG | 2020 | $1.4B | — |
| Boehringer Ingelheim GmbH / Yuhan Corporation | 2019 | $870M | — |
| AstraZeneca PLC / Daiichi Sankyo Company, Limited | 2019 | $6.9B | 100 |
← Browse all deals · How we score deals
More: 2020 deals · Boehringer Ingelheim GmbH deals · Oncology deals